Leerink Partners reiterated an Outperform rating and $530.00 price target on Regeneron Pharma (NASDAQ: REGN) after Regeneron and Sanofi reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Regeneron (REGN), Sanofi (SNY) Announce Publication of Positive Dupixent Phase 3 Data as AD TreatmentOctober 3, 2016 6:32 AM Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of MedicineOctober 1, 2016 2:00 AM Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMDSeptember 30, 2016 10:16 AM Pre-Open Stock Movers 09/30: (LXK) (AUPH) (DB) Higher; (OPHT) (CAMP) (CTSH) Lower (more...)September 30, 2016 9:17 AM Leerink Positive on Ophthotech (OPHT) Amid Regeneron (REGN) FailureSeptember 30, 2016 8:58 AM Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo DataSeptember 30, 2016 8:05 AM Regeneron (REGN) Announces EYLEA Phase 2 CAPELLA Missed Primary Endpoint in Neovascular Age-Related Macular DegenerationSeptember 30, 2016 7:01 AM Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular DegenerationSeptember 30, 2016 7:00 AM